Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Recombinant factor IX

G C White¹, A Beebe, B Nielsen

¹Department of Medicine, University of North Carolina, Chapel Hill, USA.

Thrombosis and Haemostasis

|July 1, 1997

Summary

This summary is machine-generated.

Recombinant factor IX (rFIX) offers a safe and effective treatment for hemophilia B. This new therapy provides a crucial alternative for patients, comparable to plasma-derived factor IX.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The value of early root development traits in breeding programs for biomass yield in perennial ryegrass (Lolium perenne L.).

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2025

Same author

Impact of early inoculation of probiotics to suckling piglets on postweaning diarrhoea - A challenge study with Enterotoxigenic E. Coli F18.

Animal : an international journal of animal bioscience·2022

Same author

The impact of two commonly used neutralizing agents in water sampling bottles on legionella and pseudomonas bacteria recovery.

The Journal of hospital infection·2021

Same author

Screening of probiotic candidates in a simulated piglet small intestine in vitro model.

FEMS microbiology letters·2021

Same author

Functional in vitro screening of probiotic strains for inoculation of piglets as a prophylactic measure towards Enterotoxigenic Escherichia coli infection.

Journal of microbiological methods·2020

Same author

Transport of valine across the small intestinal epithelium in pigs fed different valine levels and Bacillus subtilis.

Journal of animal physiology and animal nutrition·2017

Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026

Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026

Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026

Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026

Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026

Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026

See all related articles

Area of Science:

Biotechnology
Hematology
Pharmacology

Background:

Hemophilia B patients face risks from blood-borne viruses due to limited recombinant factor IX options.
Existing treatments for hemophilia B have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

To evaluate the clinical utility and safety of a newly licensed recombinant factor IX preparation, BeneFix.
To compare the characteristics of recombinant factor IX with plasma-derived factor IX.

Main Methods:

Pharmacokinetic studies were conducted to assess the recovery and behavior of recombinant factor IX.
Structural and functional analyses were performed to compare recombinant and plasma-derived factor IX.

Main Results:

Related Experiment Videos

Recombinant factor IX (BeneFix) demonstrated structural, functional, and therapeutic comparability to plasma-derived factor IX.
Pharmacokinetic studies showed approximately 72% recovery for recombinant factor IX compared to plasma-derived factor IX, attributed to post-translational modification differences.
Recombinant factor IX exhibited an expected safety profile for a product derived from recombinant technology.

Conclusions:

Recombinant factor IX is an effective treatment for hemophilia B.
BeneFix provides a safe and clinically viable option for hemophilia B patients, addressing a critical unmet need.